KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB:GCAN), a developer of immunotherapies for the treatment of cancer, today announced that Patrick Schnegelsberg, Chief Executive Officer, is scheduled to present VitiGam™, GammaCan’s lead product under development for the treatment of Stage III and Stage IV melanoma at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference. GammaCan’s presentation is scheduled for Monday, May 14th at 2:55 PM CST (8:55 AM EDT).
